Nuvalent, Inc. (NUVL)
Jul 15, 2026 - NUVL was delisted (reason: acquired by GSK)
123.96
+0.02 (0.02%)
Inactive · Last trade price on Jul 14, 2026

Nuvalent Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
9,8347,8705,5854,7151,688920
Market Cap Growth
71.88%40.92%18.46%179.36%83.52%-
Enterprise Value
8,5476,4984,4673,9951,215631.47
Last Close Price
123.96100.5978.2873.5929.7819.04

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
8.336.305.226.733.653.23
P/TBV Ratio
7.865.864.866.123.201.46

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Debt / Equity Ratio
-1.10-1.10-1.04-1.03-1.02-1.01
Net Debt / EBITDA Ratio
2.933.313.994.825.486.29
Net Debt / FCF Ratio
4.124.996.047.227.277.20
Quick Ratio
15.8815.0520.7022.6224.2432.79
Current Ratio
16.1415.2720.9622.8324.5433.07
Return on Equity (ROE)
-37.15%-36.70%-29.46%-21.70%-21.89%-32.06%
Return on Assets (ROA)
-32.03%-32.48%-30.01%-24.61%-22.18%-30.10%
Return on Capital Employed (ROCE)
-34.13%-34.39%-31.36%-25.70%-23.02%-31.46%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Buyback Yield / Dilution
-9.05%-9.45%-14.06%-17.22%-128.01%-659.75%
Total Shareholder Return
-9.05%-9.45%-14.06%-17.22%-128.01%-659.75%
SEC Filings: 10-K · 10-Q